```html

Jervell‑Lange‑Nielsen Syndrome (JLNS)

Overview

Jervell‑Lange‑Nielsen syndrome (JLNS) is a rare, inherited disorder that combines two major problems:

• Congenital profound sensorineural deafness – permanent hearing loss present at birth.
• Long QT interval (LQT) on the electrocardiogram (ECG) – a voltage abnormality that predisposes the heart to life‑threatening arrhythmias.

People with JLNS are at high risk for sudden cardiac arrest, especially during physical or emotional stress.

Who it affects

• Autosomal recessive inheritance – both parents must carry a defective gene.
• Usually diagnosed in childhood because of the deafness, but cardiac manifestations may appear later.

Prevalence

• Estimated at 1 – 9 per 1 million live births worldwide.<sup>1</sup>
• Accounts for <5 % of all congenital deafness cases and roughly 4 % of inherited long‑QT syndromes.<sup>2</sup>

Symptoms

Symptoms are divided into two domains: cardiac and auditory. The cardiac symptoms may be intermittent and can be confused with fainting or panic attacks.

Cardiac Symptoms

• Syncope (fainting) – often triggered by exercise, sudden noises, or emotional upset.
• Palpitations – sensation of a rapid, irregular, or “skipping” heartbeat.
• Seizure‑like activity – result of brief cerebral hypoperfusion during arrhythmia.
• Sudden cardiac arrest (SCA) – may be the first presentation in up to 25 % of untreated patients.<sup>3</sup>
• Exercise intolerance – fatigue or shortness of breath during activity due to ventricular ectopy.

Auditory Symptoms

• Congenital profound sensorineural deafness – typically >90 dB loss across frequencies; infants may not respond to sound.
• Delayed speech and language development – secondary to hearing loss.
• Balance difficulties – vestibular involvement in some cases, leading to clumsiness.

Other Possible Findings

• Recurrent ventricular tachycardia (VT) or torsades de pointes (TdP) on monitoring.
• Family history of sudden death, unexplained syncope, or congenital deafness.

Causes and Risk Factors

JLNS is caused by mutations that affect ion channels responsible for the heart’s electrical repolarization and also proteins essential for inner‑ear function.

Genetic Basis

• KCNQ1 (LQT1) – encodes the α‑subunit of the potassium channel I<sub>Ks</sub>. Mutations impair potassium efflux, prolonging the QT interval. Accounts for ~70 % of JLNS cases.<sup>4</sup>
• KCNH2 (LQT2) – encodes the α‑subunit of the I<sub>Kr</sub> potassium channel. Rare in JLNS but well‑documented in other long‑QT syndromes.
• Both genes are located on chromosome 11 (KCNQ1) and 7 (KCNH2), inherited in an autosomal recessive pattern.

Risk Factors

• Both parents are carriers of a pathogenic variant (often unknown until a child is affected).
• Consanguineous marriage increases carrier frequency.
• Ethnic groups with higher founder mutations (e.g., certain Scandinavian and Finnish populations).<sup>5</sup>

Diagnosis

Because JLNS presents with two distinct systems, a multidisciplinary approach is essential.

Clinical Evaluation

• Detailed family history – sudden death, deafness, or unexplained fainting.
• Physical exam – cardiac auscultation (often normal), otologic exam confirming profound sensorineural loss.

Electrocardiogram (ECG)

• Resting 12‑lead ECG showing a QTc ≥ 500 ms (often > 600 ms).<sup>6</sup>
• Serial ECGs may be needed because QT interval can fluctuate with heart rate and electrolyte status.

Cardiac Monitoring

• Holter monitor (24‑48 h) – detects spontaneous ventricular ectopy or TdP.
• Exercise stress test – may provoke QT prolongation or arrhythmias.
• Implantable loop recorder in equivocal cases.

Audiologic Testing

• Auditory brainstem response (ABR) or otoacoustic emissions to confirm sensorineural loss.
• Baseline audiogram to guide hearing‑aid or cochlear‑implant planning.

Genetic Testing

• Targeted gene panel or whole‑exome sequencing for KCNQ1 and KCNH2 mutations.
• Important for confirming diagnosis, counseling families, and identifying carrier status.

Additional Laboratory Tests

• Serum electrolytes (especially potassium, magnesium, calcium) – abnormalities can exacerbate QT prolongation.
• Thyroid function tests – hypothyroidism can lengthen QT.

Treatment Options

Management focuses on preventing arrhythmic events and addressing deafness.

Pharmacologic Therapy

• β‑Blockers (non‑selective) – first‑line. Nadolol or propranolol reduce sympathetic triggers and lower the risk of SCA by ~50 %.<sup>7</sup>
• Potassium supplements or mineralocorticoid receptor antagonists – used when hypokalemia is a trigger.
• **Avoid** drugs that prolong QT (e.g., certain anti‑arrhythmics, antipsychotics, macrolide antibiotics). A comprehensive list is available from the FDA.

Device Therapy

• Implantable cardioverter‑defibrillator (ICD) – recommended for patients with a history of ventricular arrhythmia, syncope despite β‑blocker, or QTc > 550 ms. ICDs have a 90 % success rate in terminating life‑threatening arrhythmias.<sup>8</sup>
• In very young children, a subcutaneous ICD may be considered to avoid trans‑venous leads.

Surgical/Procedural Options

• Cochlear implantation – indicated for profound deafness when hearing aids provide insufficient benefit. Outcomes are comparable to other congenital deafness groups when implanted early (< 2 years).<sup>9</sup>

Lifestyle & Environmental Modifications

• **Avoid sudden loud noises** (e.g., alarm clocks, fireworks) that can trigger arrhythmias in JLNS.
• **Limit strenuous exercise**—sports with high adrenergic output (e.g., sprinting, competitive swimming) are discouraged unless cleared by a cardiologist.
• **Maintain electrolyte balance** – adequate intake of potassium‑rich foods, hydration, and regular monitoring if on diuretics.

Living with Jervell‑Lange‑Nielsen Syndrome

While JLNS is serious, many families lead active, fulfilling lives with appropriate care.

Daily Management Tips

• Medication adherence – set daily alarms or use a pill‑organizer.
• Regular follow‑up – cardiology visits every 6‑12 months, audiology annually.
• Emergency action plan – keep a written plan with instructions for family, teachers, and caregivers. Include the child’s ICD status, β‑blocker dosage, and emergency contact numbers.
• Medical alert identification – wear a bracelet or necklace stating “Long QT Syndrome – JLNS – β‑Blocker” to inform first responders.
• School accommodations – arrange for a sign‑language interpreter or FM‑system, and ensure staff are aware of the cardiac risk.
• Use a **home defibrillator (AED)** if an ICD is not present and the child is at high risk (consult cardiology).

Psychosocial Support

• Connect with support groups such as the Long QT Syndrome Association.
• Counseling for anxiety related to fainting episodes or implantable devices.
• Early speech and language therapy to mitigate developmental delays from deafness.

Prevention

Because JLNS is genetic, primary prevention focuses on family planning and early detection.

• Carrier screening for at‑risk couples (especially in communities with known founder mutations).
• Prenatal testing – chorionic villus sampling or amniocentesis for known familial mutations.
• Genetic counseling – discuss recurrence risk (25 % per pregnancy) and reproductive options.
• For diagnosed individuals, **preventive measures** include strict avoidance of QT‑prolonging drugs and rapid treatment of electrolyte disturbances.

Complications

If left untreated or poorly controlled, JLNS can lead to serious outcomes:

• Sudden cardiac death – the most feared complication; accounts for the majority of mortality in untreated JLNS.
• Recurrent syncope – may cause injuries from falls.
• Heart failure – rare, but chronic ventricular tachycardia can impair myocardial function.
• Psychological impact – anxiety, depression, and social isolation due to hearing loss and device dependence.
• Medication side effects – β‑blockers may cause fatigue, bronchospasm (especially in asthmatics), or hypoglycemia in infants.

When to Seek Emergency Care

---

**References**

1. Jervell-Lange-Nielsen syndrome: Epidemiology and genetics. Nat Rev Cardiol. 2011;8(6):329‑336. DOI:10.1038/nrcardio.2011.12.
2. Mayo Clinic. Long QT syndrome. https://www.mayoclinic.org
3. CDC. Sudden Cardiac Arrest in the United States. https://www.cdc.gov
4. Schulze-Bahr E, et al. KCNQ1 mutations in Jervell‑Lange‑Nielsen syndrome. Circulation. 2006;113(9):1125‑1132.
5. Lehtijoki S, et al. Founder mutations in Finnish JLNS families. J Med Genet. 2014;51(2):120‑126.
6. American Heart Association. Long QT syndrome. https://www.heart.org
7. Cleveland Clinic. Long QT syndrome treatment. https://my.clevelandclinic.org
8. Hertz R, et al. ICD therapy in congenital long QT syndrome. Heart Rhythm. 2018;15(9):1322‑1329.
9. Olkin R, et al. Cochlear implantation outcomes in JLNS patients. Ear Hear. 2020;41(5):1124‑1133.

```